Multiple sclerosis

Current Care Summary
Working group appointed by the Finnish Medical Society Duodecim and the Finnish Neurological Society
5.2.2019

Current Care Guideline «MS-tauti»1 and Summary in Finnish «MS-tauti»2

Treatment for relapsing-remitting multiple sclerosis (RRMS) is initiated upon fulfillment of new McDonald 2017 criteria, including lumbar puncture. At the time of diagnosis RRMS is classified as active or highly active based on the relapse rate and magnetic resonance imaging findings. For active RRMS, interferon-β, dimethyl fumarate, glatiramer acetate, ocrelizumab and teriflunomide are recommended treatments. For highly active disease, whether on previous immunomodulating drug treatment or not, alemtuzumab, cladribine, fingolimod, natalizumab or ocrelizumab are recommended. Ocrelizumab may also be used for primary progressive MS. Rehabilitation should be considered at every phase of the disease.

Anne Remes (Chair)

Sari Atula

Laura Airas

Juha-Pekka Erälinna

Päivi Hartikainen

Eliisa Mäenpää

Juhani Ruutiainen

Mervi Ryytty

Raija Sipilä

Maritta Ukkonen